News & Updates

Abrocitinib effectively controls AD regardless of dosing regimen
Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023 byAudrey Abella

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

Abrocitinib effectively controls AD regardless of dosing regimen
03 Aug 2023
Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis
Ustekinumab safe, effective in Asians with moderate to severe plaque psoriasis
14 Jul 2023